Skip to content
DataLookout
Menu

CLARITY-101NCT07849231

A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 4 → 36 locations
  2. Minor Study title shortened, about 4 words
  3. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

To evaluate the safety and tolerability of DMR-001 & determine the MTD, RDE(s), and/or recommended Phase 2 dose(s) in participants with CALR-mutant MPNs, when administered as monotherapy or in combination with ruxolitinib
Timeframe: Up to 672 days

Secondary (7)

Evaluate preliminary clinical activity of DMR-001 as a monotherapy in participants with CALR-mutant ET
Evaluate preliminary clinical activity of DMR-001 as a monotherapy or in combination with ruxolitinib in participants with CALR-mutant MF
Pharmacokinetics parameter: Cmax of DMR-001 when administered as monotherapy or in combination with ruxolitinib
Pharmacokinetics parameter: Tmax of DMR-001 when administered as monotherapy or in combination with ruxolitinib
Pharmacokinetics parameter: AUC(0-t) of DMR-001 when administered as monotherapy or in combination with ruxolitinib
Show 2 moreShow less
Pharmacokinetics parameter: t1/2 of DMR-001 when administered as monotherapy or in combination with ruxolitinib
Assess the immunogenicity of DMR-001

Arms and interventions

Part 1: DMR-001 monotherapy dose escalation phase.Experimental

DMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the protocol defined starting dose and dosing schedule to identify the maximum tolerated dose and/or recommended dose(s) for expansion.

Part 2: DMR-001 monotherapy dose expansion phase.Experimental

DMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the determined recommended dose(s) for expansion based on Part 1.

Part 3: DMR-001 and ruxolitinib combination dose escalation followed by dose expansion.Experimental

DMR-001 will be administered starting once every 4 weeks as a subcutaneous injection at the determined dose and regimen, but in combination with an oral tablet of ruxolitinib, a standard of care drug approved therapy for the treatment of MF.

Drugs: DMR-001, Ruxolitinib

Sites

36 sites in 2 countries

United States 25, Australia 11